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those with a history of CVD. CONCLUSIONS: In each subgroup, there was a sub-
stantial improvement in LDL-C, while improvement of TG and HDL-C levels were 
moderate and negligible, respectively. Despite LMT, both single and mixed dyslipid-
emias were prevalent among high risk patients, particularly among those with DM 
and even more so among those with FRS > 20%. While the prevalence and persistence 
of dyslipidemia varied between groups, observations suggest that all may beneﬁ t from 
other types of LMT in addition to statins.
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OBJECTIVES: Antihypertensive agents (AH) have been shown to reduce the risk of 
major cardiovascular (CVD) events. However, there is no large scale effectiveness 
studies which have assessed the relationship between adherence to AH medications 
and major CVD outcomes in high risk individuals that have suffered an ischemic 
stroke. The aim of the study was to evaluate the relationship between AH drug adher-
ence and vascular outcomes in a cohort of older patients hospitalized for an ischemic 
stroke and discharged in the community. METHODS: A cohort of 14,227 patients 
with ischemic stroke was reconstructed from RAMQ and Med-Echo databases. Eli-
gible subjects were 65 years and older and treated with AH agents between 1999 and 
2007. A nested case-control design was used to study major CVD outcomes. Every 
case was matched for age and duration of follow-up. The adherence to AH drugs was 
measured as the proportion of days’ supply of medication dispensed over a deﬁ ned 
period. Conditional logistic regression models were used to estimate the rate ratio of 
vascular events adjusting for covariables. RESULTS: Mean patient age was 75 years, 
54% were male, 23% had diabetes, and 47% had dyslipidemia, 38% had CAD, 6% 
MI and 14% had atrial ﬁ brillation. Adherence to AH agents ≥80% reduced the risk 
of vascular events (RR: 0.70; 0.64–0.77) compared to the one of <80%. Male gender, 
prior CVD, and non adherence to therapies for diabetes and dyslipidemia were risk 
factors. CONCLUSIONS: Higher adherence to AH therapy is linked with a risk 
reduction of vascular events among patients with ischemic stroke.
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OBJECTIVES: The correlation between severity of hypertension and risk of end-stage 
renal disease (ESRD) is well known. However, the impact of antihypertensive drug 
adherence on primary prevention of chronic kidney disease (CKD) has never been 
assessed. Our objective was to evaluate the impact of better adherence to antihyper-
tensive (AH) therapy on ESRD. METHODS: A cohort of 208,128 patients was 
reconstructed using RAMQ and MedEcho databases. Patients were eligible if they 
were between 45 to 85 years of age, had a new diagnosis of hypertension and were 
newly treated with AH drug between 1999 and 2007. a nested case-control design 
was used to study the occurrence of ESRD. Every case of ESRD was matched for age 
and duration of follow-up. Adherence level was assessed as a medication possession 
ratio. Conditional logistic regression models were used to estimate the rate ratio of 
ESRD adjusting for several covariables. RESULTS: Patients were at 65 years old and 
42% male. The mean high adherence level (80%) to AH therapy was 90%. We identi-
ﬁ ed 1026 cases with ESRD during follow-up. High adherence level (80%) to AH 
therapy compared to lower adherence level (<80%) was associated with a reduction 
of ESRD (RR: 0.81; 0.70–0.95). Risk factors for ESRD were CKD, gout, diabetes, 
coronary artery disease, chronic heart failure and peripheral vascular disease. CON-
CLUSIONS: The study suggests that better adherence to AH therapy is associated 
with risk reduction of new onset ESRD in hypertensive population.
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Dronedarone is a new antiarrhythmic drug developed for the treatment of atrial ﬁ bril-
lation (AF). While numerous large cardiovascular (CV) clinical trials have assessed the 
efﬁ cacy of different compounds on morbidity and mortality endpoints, dronedarone 
is the ﬁ rst antiarrhythmic drug for AF for which a large randomized clinical trial 
(ATHENA) was designed to assess morbidity/mortality endpoints. OBJECTIVES: To 
perform an effectiveness analysis using the Number Needed to Treat (NNT) approach 
to compare dronedarone with other CV drugs in avoiding major CV events (CV death, 
CV hospitalization and stroke). METHODS: A literature search for 3 CV active 
medications (statins, angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers) was performed using PubMed from 1995 to present to identify clinical trials 
with endpoints comparable to those of ATHENA. NNTs were calculated using hazard 
ratios; different lengths of follow up were adjusted to one year, dividing each rate of 
events by the study duration. RESULTS: Twenty clinical trials were identiﬁ ed as 
having at least one endpoint comparable to ATHENA. Based on the ATHENA data, 
the NNT per year of treatment with dronedarone to avoid one “CV death”, one “CV 
hospitalization” and one stroke were 157, 11, and 172, respectively. Dronedarone 
was associated with a lower NNT to avoid a “CV death” compared to ramipril 
(HOPE, NNT = 239), pravastatin (LIPID, NNT = 255), and simvastatin (HPS, NNT 
= 325; 4S, NNT = 167), but a higher NNT vs. candesartan in selected chronic heart 
failure patients (CHARM, NNT = 123). NNTs for dronedarone to avoid one “CV 
hospitalization” and one stroke compared favorably to the other medications evalu-
ated. CONCLUSIONS: Pressure on health care budgets emphasizes the need to dem-
onstrate medical value, notably through NNTs which enable comparisons across 
interventions. Dronedarone has morbidity/mortality data (“CV death”, “CV hospital-
izations” and stroke) that compares favorably in terms of NNT to other CV therapies 
within their respective trial patient populations.
PCV22
THE INFLUENCE OF METEOROLOGICAL FACTORS ON CEREBRAL 
INFARCTION, INTRACEREBRAL HEMORRHAGE, SUBARACHNOID 
HEMORRHAGE AND TRANSIENT ISCHEMIC ATTACK
Kriszbacher I1, Csoboth I1, Fülöp A2, Boncz I1, Köhalmi A1, Müller Á1, Bódis J1
1University of Pécs, Pécs, Hungary; 2National Meteorological Service, Budapest, Hungary
OBJECTIVES: We have investigated, whether the time of onset of an acute cerebro-
vascular event demonstrates a seasonal variation, and whether it is inﬂ uenced by 
meteorological factors. METHODS: We examined patients admitted to Neurology 
Departments in Hungary between 2005 and 2007 with the diagnose of cerebral infarc-
tion, intracerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack 
(n = 178,092). Data was collected from the database of the Hungarian National Health 
Insurance Fund based on the International Classiﬁ cation of Diseases. Meteorological 
data was retrieved from the National Meteorology Service. RESULTS: Meteorological 
analysis showed, that an increase in average temperature on the previous day resulted 
in a signiﬁ cant drop of intracerebral hemorrhage incidence during Spring, Summer 
and Autumn (P < 0.01), while in case of cerebral infarction such decrease only 
occurred during Summer and Winter (P < 0.01), and for transient ischemic attack, 
only during Summer (P < 0.01).Examining atmospheric pressure, we found variations 
in case of cerebral infarction, intracerebral hemorrhage and transient ischemic attack. 
Morbidity rates of cerebral infarction increased during Summer, and decreased during 
Winter, whenever average atmospheric pressure values on the preceding day were 
higher (P < 0.01). Decrease in morbidity rates was observed for intracerebral hemor-
rhage and transient ischemic attack (P < 0.01). Considering relative humidity on the 
previous day, a marked variation showed for cerebral infarction during Spring (P < 
0.01), and for intracerebral hemorrhage during Summer (P < 0.01). No relationship 
was found with subarachnoid hemorrhage. CONCLUSIONS: Results reveal, that the 
occurrence cerebrovascular events shows typical variations depending on the season 
of the year, while certain meteorological factors inﬂ uence the development these also.
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OBJECTIVES: To assess what proportion of patients treated with low-dose acetyl-
salicylic acid (ASA) for secondary prevention of cardiovascular events discontinue this 
treatment, and to identify risk factors for discontinuation. METHODS: The Health 
Improvement Network UK primary care database was used to identify individuals 
aged 50–84 years with ≥2 prescriptions of low-dose ASA (75–300 mg/day) in 2000–
2007 (n = 35,639). The study cohort was followed from the ﬁ rst day after the initial 
prescription until the earliest occurrence of one of the following: ASA discontinuation 
(a period of ≥90 days after the last prescription would have been used up [assuming 
full compliance], with no reﬁ ll of the prescription during this time); death; diagnosis 
of an alcohol-related condition or cancer; or the end of the study period. The mean 
follow-up time was 2.5 years. RESULTS: Almost one-third of patients discontinued 
low-dose ASA (n = 11,729; incidence: 13.1 per 100 person-years; 95% conﬁ dence 
interval [CI]: 12.9–13.4). The incidence of discontinuation was higher in the ﬁ rst year 
of follow-up (26.7 per 100 person-years; 95% CI: 26.1–27.3) than the rest of the 
study period (6.8 per 100 person-years; 95% CI: 6.6–7.0). The risk of discontinuation 
was 42–67% higher in patients with an initial indication of unstable angina, ischemic 
heart disease or cerebrovascular disease than those with an initial indication of myo-
cardial infarction. Current use of proton pump inhibitors (PPIs) was associated with 
a signiﬁ cant reduction in the risk of discontinuation (odds ratio [OR]: 0.92; 95% CI: 
0.87–0.98; compared with no PPI use). Individuals taking PPIs from the same time as 
their ASA treatment were at particularly low risk of ASA discontinuation (OR: 0.74; 
95% CI: 0.69–0.79). CONCLUSIONS: Discontinuation of low-dose ASA treatment 
is common, especially in the ﬁ rst year of treatment. Concomitant PPI use reduces the 
risk of ASA discontinuation.
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OBJECTIVES: Randomized clinical trial comparing percutaneous coronary interven-
tions (PCI) and non-invasive treatment acute coronary syndromes mostly favour the 
